Rucaparib

Rucaparib
Names
Pronunciation/ruːˈkæpərɪb/ roo-KAP-ər-ib
Trade namesRubraca
Other namesAG014699
IUPAC name
  • 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Clinical data
Drug classPARP inhibitor[1]
Main usesOvarian cancer, fallopian tube cancer, peritoneal cancer, prostate cancer[1][2]
Side effectsTiredness, nausea, kidney problems, liver problems, low red blood cells, abnormal taste, diarrhea, low platelets, abdominal pain[3]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: N (Not classified yet)
  • Not recommended
Routes of
use		By mouth (tablets)
Typical dose600 mg BID[3]
External links
AHFS/Drugs.comMonograph
MedlinePlusa617002
Legal
License data
Legal status
  • UK: POM (Prescription only) [4]
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetics
Bioavailability30–45% (Tmax = 1.9 hours)
Protein binding70% (in vitro)
MetabolismLiver (primarily CYP2D6; 1A2 and 3A4 to a lesser extent)
Elimination half-life17–19 hours[1]
Chemical and physical data
FormulaC19H18FN3O
Molar mass323.371 g·mol−1
3D model (JSmol)
SMILES
  • CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34
InChI
  • InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
  • Key:HMABYWSNWIZPAG-UHFFFAOYSA-N

Rucaparib, sold under the brand name Rubraca, is a medication used for ovarian cancer, fallopian tube cancer, peritoneal cancer, and prostate cancer.[1][2] It is used after other treatments have failed.[3] It is taken by mouth.[1]

Common side effects include tiredness, nausea, kidney problems, liver problems, low red blood cells, abnormal taste, diarrhea, low platelets, and abdominal pain.[3] Other side effects may include acute myeloid leukemia and low neutrophils.[5] Use during pregnancy may harm the baby.[5] It is a PARP inhibitor, which block DNA repair in cells with mutation in the BRCA gene.[1]

Rucaparib was approved for medical use in the United States in 2016 and Europe in 2018.[5][3] In the United States it costs about 9,100 USD per month as of 2021.[6]

Medical uses

Rucaparib is indicated as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.[7][1][8]

Rucaparib is indicated as monotherapy treatment of adults with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.[7][1]

Dosage

It is taken at a dose of 600 mg twice per day.[3]

Pharmacology

Mechanism of action

Rucaparib inhibits "the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture."[9]

As a PARP inhibitor, rucaparib is expected to be more effective in the 9% of pancreatic cancers with a BRCA mutation (BRCA1 or BRCA2).[10]

History

It was discovered as part of a collaboration between scientists working at the Northern Institute of Cancer Research and Medical School of Newcastle University and Agouron Pharmaceuticals in San Diego, California.[11] It is being developed by Clovis Oncology.

In December 2016, the US Food and Drug Administration (FDA) granted an accelerated approval for use in cases of pretreated advanced ovarian cancer.[12][13]

In the European Union it was designated an orphan medicinal product on 10 October 2012. On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation, intended for the treatment of relapsed or progressive ovarian cancer.[14][7] It was approved for medical use in the European Union in May 2018.[7]

Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1).

Research

After the FDA approval, TRITON2 and TRITON3 mCRPC studies were initiated in order to determine how patients with prostate cancer will respond to the rucaparib drug. The studies for these two trials are still going on and the estimated dates for the first results are range between 2019 and 2022.[15]

The ARIEL3 and ARIEL4 are two randomized, double-blind phase III studies. The ARIEL3 study was designed to evaluate the effect of the investigational agent as a maintenance treatment for the advanced platinum-sensitive ovarian cancer patients compared placebo after their response to at least two prior chemotherapies. The top-line results from the study were presented at the ESMO 2017 congress and right after that, it was published in the Lancet journal in September 2017. The findings showed significant improvement in progression-free survival (PFS) in patients treated with Rubraca than placebo. Recently, in October 2017, a supplemental sNDA for the rucaparib ARIEL3 maintenance treatment has been submitted to the FDA.[16]

The ARIEL4 trial is still ongoing to evaluate how patients will best respond to treatment with rucaparib compared with chemotherapy. The estimated data collection date for primary outcome measurement will be in June 2022.[17]

References

  1. 1 2 3 4 5 6 7 8 "DailyMed - RUBRACA- rucaparib tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 9 May 2020. Retrieved 19 October 2021.
  2. 1 2 "Rucaparib Camsylate - National Cancer Institute". www.cancer.gov. 3 January 2017. Archived from the original on 9 July 2021. Retrieved 19 October 2021.
  3. 1 2 3 4 5 6 "Rubraca". Archived from the original on 6 August 2020. Retrieved 19 October 2021.
  4. ↑ "Rubraca 200mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Archived from the original on 29 August 2021. Retrieved 17 May 2020.
  5. 1 2 3 "Rucaparib Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 19 October 2021.
  6. ↑ "Rubraca Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 20 March 2021. Retrieved 19 October 2021.
  7. 1 2 3 4 "Rubraca EPAR". European Medicines Agency (EMA). Archived from the original on 6 August 2020. Retrieved 17 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ↑ "FDA approves rucaparib". U.S. Food and Drug Administration (FDA) (Press release). 6 April 2018. Archived from the original on 17 May 2020. Retrieved 17 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  9. ↑ "Does the PARP inhibitor AG014699 act via the nucleotide P2 receptor?" (PDF). School of Pharmacy - PhD Projects 2009. Archived from the original (PDF) on 13 June 2011. Retrieved 17 November 2009.
  10. ↑ "Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation". sciencedaily.com. Archived from the original on 17 August 2019. Retrieved 17 April 2021.
  11. ↑ White AW, Almassy R, Calvert AH, Curtin NJ, Griffin RJ, Hostomsky Z, et al. (November 2000). "Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase". Journal of Medicinal Chemistry. 43 (22): 4084–97. doi:10.1021/jm000950v. PMID 11063605.
  12. ↑ Bankhead C (19 December 2016). "PARP Inhibitor Gets FDA Nod for Ovarian Cancer". MedPage Today, LLC. Archived from the original on 20 December 2016. Retrieved 20 December 2016.
  13. ↑ "Rubraca (rucaparib) Tablets". U.S. Food and Drug Administration (FDA). 30 January 2017. Archived from the original on 1 April 2021. Retrieved 17 May 2020.
  14. ↑ "Rubraca". European Medical Agency. 22 March 2018. Archived from the original on 29 May 2018.
  15. ↑ ""Rucaparib Clinical Overview" (PDF). Clovis Oncology. Archived from the original (PDF) on 13 April 2018.
  16. ↑ Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. (October 2017). "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial". Lancet. 390 (10106): 1949–1961. doi:10.1016/S0140-6736(17)32440-6. PMC 5901715. PMID 28916367.
  17. ↑ "Ledermann J, Oza AM, Lorusso D (November 2017). "ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)" (PDF): 28. Archived (PDF) from the original on 26 July 2019. Retrieved 17 April 2021. {{cite journal}}: Cite journal requires |journal= (help)
External sites:
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.